{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:21:16Z","timestamp":1787642476019,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10549-026-08054-9","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:45:50Z","timestamp":1786520750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction"],"prefix":"10.1007","volume":"218","author":[{"given":"Tyler P.","family":"Shern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan R.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele A.","family":"Gadd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francys C.","family":"Verdial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"Ozmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C.","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"1","key":"8054_CR1","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon S, Labarriere N (2017) PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? Oncoimmunology 7(1):e1364828. https:\/\/doi.org\/10.1080\/2162402X.2017.1364828","journal-title":"Oncoimmunology"},{"issue":"1","key":"8054_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P et al (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23(1):108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"issue":"7","key":"8054_CR3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.jpain.2023.02.002","volume":"24","author":"L Zhao","year":"2023","unstructured":"Zhao L, Ma Y, Song X, Wu Y, Jin P, Chen G (2023) PD-1: A New Candidate Target for Analgesic Peptide Design. J Pain 24(7):1142\u20131150. https:\/\/doi.org\/10.1016\/j.jpain.2023.02.002","journal-title":"J Pain"},{"issue":"9","key":"8054_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"19","key":"8054_CR5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 375(19):1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"issue":"11","key":"8054_CR6","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/medicina58111572","volume":"58","author":"FK Alkholifi","year":"2022","unstructured":"Alkholifi FK, Alsaffar RM (2022) Dostarlimab an Inhibitor of PD-1\/PD-L1: A New Paradigm for the Treatment of Cancer. Med (Kaunas) 58(11):1572. https:\/\/doi.org\/10.3390\/medicina58111572","journal-title":"Med (Kaunas)"},{"issue":"23","key":"8054_CR7","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM et al (2023) Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med 388(23):2145\u20132158. https:\/\/doi.org\/10.1056\/NEJMoa2216334","journal-title":"N Engl J Med"},{"issue":"2","key":"8054_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi S, Salgado R, Curigliano G et al (2025) Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat Med 31(2):433\u2013441. https:\/\/doi.org\/10.1038\/s41591-024-03414-8","journal-title":"Nat Med"},{"issue":"2","key":"8054_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834014567470","volume":"7","author":"R Sundar","year":"2015","unstructured":"Sundar R, Cho BC, Brahmer JR, Soo RA (2015) Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 7(2):85\u201396. https:\/\/doi.org\/10.1177\/1758834014567470","journal-title":"Ther Adv Med Oncol"},{"issue":"26","key":"8054_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"issue":"26","key":"8054_CR11","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465. https:\/\/doi.org\/10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"issue":"1","key":"8054_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/PPO.0000000000000299","volume":"24","author":"RR Munhoz","year":"2018","unstructured":"Munhoz RR, Postow MA (2018) Clinical Development of PD-1 in Advanced Melanoma. Cancer J 24(1):7\u201314. https:\/\/doi.org\/10.1097\/PPO.0000000000000299","journal-title":"Cancer J"},{"issue":"20","key":"8054_CR13","doi-asserted-by":"publisher","first-page":"e137386","DOI":"10.1172\/jci.insight.137386","volume":"5","author":"BL Liu","year":"2020","unstructured":"Liu BL, Cao QL, Zhao X, Liu HZ, Zhang YQ (2020) Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia. JCI Insight 5(20):e137386. https:\/\/doi.org\/10.1172\/jci.insight.137386","journal-title":"JCI Insight"},{"issue":"7","key":"8054_CR14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nn.4571","volume":"20","author":"G Chen","year":"2017","unstructured":"Chen G, Kim YH, Li H et al (2017) PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci 20(7):917\u2013926. https:\/\/doi.org\/10.1038\/nn.4571","journal-title":"Nat Neurosci"},{"issue":"531","key":"8054_CR15","doi-asserted-by":"publisher","first-page":"eaaw6471","DOI":"10.1126\/scitranslmed.aaw6471","volume":"12","author":"Z Wang","year":"2020","unstructured":"Wang Z, Jiang C, He Q et al (2020) Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates. Sci Transl Med 12(531):eaaw6471. https:\/\/doi.org\/10.1126\/scitranslmed.aaw6471","journal-title":"Sci Transl Med"},{"key":"8054_CR16","doi-asserted-by":"publisher","first-page":"1267532","DOI":"10.3389\/fonc.2023.1267532","volume":"13","author":"JR Scarpa","year":"2023","unstructured":"Scarpa JR, Montagna G, Plitas G, Gulati A, Fischer GW, Mincer JS (2023) Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer. Front Oncol 13:1267532. https:\/\/doi.org\/10.3389\/fonc.2023.1267532","journal-title":"Front Oncol"},{"issue":"12Supplement","key":"8054_CR17","doi-asserted-by":"publisher","first-page":"RF3","DOI":"10.1158\/1557-3265.SABCS24-RF3-01","volume":"31","author":"E Mayer","year":"2025","unstructured":"Mayer E, Graham N, Leon-Ferre RA et al (2025) Abstract RF3-01: TBCRC 056: A Phase II Study of Neoadjuvant Niraparib with Dostarlimab for Patients with BRCA- or PALB2-mutated Breast Cancer: Results From the ER+\/HER2- Cohort. Clin Cancer Res 31(12Supplement):RF3\u2013R01. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-RF3-01","journal-title":"Clin Cancer Res"},{"issue":"2","key":"8054_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, O\u2019Shaughnessy J, Liu Z et al (2025) Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial. Nat Med 31(2):442\u2013448.https:\/\/doi.org\/10.1038\/s41591-024-03415-7","journal-title":"Nat Med"},{"issue":"16suppl","key":"8054_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2025.43.16_suppl.511","volume":"43","author":"RO Abelman","year":"2025","unstructured":"Abelman RO, McLaughlin S, Fell GG et al (2025) A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG\/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. J Clin Oncol 43(16suppl):511\u2013511. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.511","journal-title":"J Clin Oncol"},{"key":"8054_CR20","unstructured":"Rappaport B (2026) ER\/LA opioid analgesic class labeling changes and postmarket requirements. Accessed June 3. https:\/\/www.fda.gov\/media\/86875\/download"},{"issue":"8","key":"8054_CR21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/s0952-8180(96)00179-1","volume":"8","author":"LG Michelsen","year":"1996","unstructured":"Michelsen LG, Hug CC Jr (1996) The pharmacokinetics of remifentanil. J Clin Anesth 8(8):679\u2013682. https:\/\/doi.org\/10.1016\/s0952-8180(96)00179-1","journal-title":"J Clin Anesth"},{"key":"8054_CR22","unstructured":"Behrends M (2026) Calculation of oral morphine equivalents (OME) | Pain management education at UCSF. Accessed June 3. https:\/\/pain.ucsf.edu\/opioid-analgesics\/calculation-oral-morphine-equivalents-ome"},{"issue":"5","key":"8054_CR23","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1245\/s10434-026-19217-9","volume":"33","author":"K Lloyd","year":"2026","unstructured":"Lloyd K, Shern TP, Holt LR et al (2026) Outpatient Mastectomy with Reconstruction at Ambulatory Surgery Centers. Ann Surg Oncol 33(5):4573\u20134583. https:\/\/doi.org\/10.1245\/s10434-026-19217-9","journal-title":"Ann Surg Oncol"},{"issue":"4, Supplement","key":"8054_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jpain.2023.02.155","volume":"24","author":"K Wang","year":"2023","unstructured":"Wang K, Deng C, Guan S, Yin Y (2023) Increased Perioperative Opioid Consumption In Patients Receiving Neoadjuvant Immunotherapy Combined With Chemotherapy For Resectable Esophageal Cancer. J Pain 24(4, Supplement):51. https:\/\/doi.org\/10.1016\/j.jpain.2023.02.155","journal-title":"J Pain"},{"issue":"8","key":"8054_CR25","doi-asserted-by":"publisher","first-page":"e14893","DOI":"10.1111\/cns.14893","volume":"30","author":"K Wang","year":"2024","unstructured":"Wang K, Er J, Zhang Y et al (2024) Increased opioid consumption in neoadjuvant immunotherapy plus chemotherapy for patients with non-small-cell lung cancer: A multicenter, prospective cohort study. CNS Neurosci Ther 30(8):e14893. https:\/\/doi.org\/10.1111\/cns.14893","journal-title":"CNS Neurosci Ther"},{"key":"8054_CR26","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.intimp.2024.111611","volume":"129","author":"H Guo","year":"2024","unstructured":"Guo H, Li Y, Lin J et al (2024) A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Int Immunopharmacol 129:111611. https:\/\/doi.org\/10.1016\/j.intimp.2024.111611","journal-title":"Int Immunopharmacol"},{"key":"8054_CR27","doi-asserted-by":"publisher","first-page":"115417","DOI":"10.1016\/j.bcp.2023.115417","volume":"209","author":"Q Sun","year":"2023","unstructured":"Sun Q, Li Z, Wang Z et al (2023) Immunosuppression by opioids: Mechanisms of action on innate and adaptive immunity. Biochem Pharmacol 209:115417. https:\/\/doi.org\/10.1016\/j.bcp.2023.115417","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"8054_CR28","doi-asserted-by":"publisher","first-page":"e009962","DOI":"10.1136\/jitc-2024-009962","volume":"12","author":"LA McIlvried","year":"2024","unstructured":"McIlvried LA, Martel Matos AA, Yuan MM et al (2024) Morphine treatment restricts response to immunotherapy in oral squamous cell carcinoma. J Immunother Cancer 12(11):e009962. https:\/\/doi.org\/10.1136\/jitc-2024-009962","journal-title":"J Immunother Cancer"},{"issue":"4","key":"8054_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.21037\/gs.2019.07.05","volume":"8","author":"G Kokosis","year":"2019","unstructured":"Kokosis G, Chopra K, Darrach H, Dellon AL, Williams EH (2019) Re-visiting post-breast surgery pain syndrome: risk factors, peripheral nerve associations and clinical implications. Gland Surg 8(4):407\u2013415. https:\/\/doi.org\/10.21037\/gs.2019.07.05","journal-title":"Gland Surg"},{"issue":"Suppl 1","key":"8054_CR30","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.4103\/joacp.JOACP_51_18","volume":"35","author":"AD Kaye","year":"2019","unstructured":"Kaye AD, Urman RD, Rappaport Y et al (2019) Multimodal analgesia as an essential part of enhanced recovery protocols in the ambulatory settings. J Anaesthesiol Clin Pharmacol 35(Suppl 1):S40\u2013S45. https:\/\/doi.org\/10.4103\/joacp.JOACP_51_18","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"2","key":"8054_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-0038-1676477","volume":"32","author":"JC Simpson","year":"2019","unstructured":"Simpson JC, Bao X, Agarwala A (2019) Pain Management in Enhanced Recovery after Surgery (ERAS) Protocols. Clin Colon Rectal Surg 32(2):121\u2013128. https:\/\/doi.org\/10.1055\/s-0038-1676477","journal-title":"Clin Colon Rectal Surg"},{"issue":"10","key":"8054_CR32","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1007\/BF03016591","volume":"48","author":"DJ Kelly","year":"2001","unstructured":"Kelly DJ, Ahmad M, Brull SJ (2001) Preemptive analgesia I: physiological pathways and pharmacological modalities. Can J Anaesth 48(10):1000\u20131010. https:\/\/doi.org\/10.1007\/BF03016591","journal-title":"Can J Anaesth"},{"key":"8054_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpra.2016.08.005","volume":"11","author":"AR Kulkarni","year":"2017","unstructured":"Kulkarni AR, Pusic AL, Hamill JB et al (2017) Factors Associated with Acute Postoperative Pain Following Breast Reconstruction. JPRAS Open 11:1\u201313. https:\/\/doi.org\/10.1016\/j.jpra.2016.08.005","journal-title":"JPRAS Open"},{"issue":"5","key":"8054_CR34","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.bjps.2015.12.009","volume":"69","author":"AA Gassman","year":"2016","unstructured":"Gassman AA, Yoon AP, Festekjian J, Da Lio AL, Tseng CY, Crisera C (2016) Comparison of immediate postoperative pain in implant-based breast reconstructions. J Plast Reconstr Aesthet Surg 69(5):604\u2013616. https:\/\/doi.org\/10.1016\/j.bjps.2015.12.009","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"8054_CR35","doi-asserted-by":"publisher","first-page":"1258287","DOI":"10.3389\/fonc.2023.1258287","volume":"13","author":"D Zou","year":"2023","unstructured":"Zou D, Wang X, Sun Y et al (2023) Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis. Front Oncol 13:1258287. https:\/\/doi.org\/10.3389\/fonc.2023.1258287","journal-title":"Front Oncol"},{"issue":"20\u201322","key":"8054_CR36","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1080\/1750743X.2024.2436838","volume":"16","author":"J Roberts","year":"2024","unstructured":"Roberts J, Barmettler S, Murray J, Melvin JE, Ye C (2024) Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis. Immunotherapy 16(20\u201322):1247\u20131254. https:\/\/doi.org\/10.1080\/1750743X.2024.2436838","journal-title":"Immunotherapy"},{"issue":"11","key":"8054_CR37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-22-0003","volume":"10","author":"CWS Wanderley","year":"2022","unstructured":"Wanderley CWS, Maganin AGM, Adjafre B et al (2022) PD-1\/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling. Cancer Immunol Res 10(11):1299\u20131308. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0003","journal-title":"Cancer Immunol Res"},{"key":"8054_CR38","doi-asserted-by":"publisher","unstructured":"Patel A, Akhade A, Parikh P et al (2022) Pembrolizumab weight based dosing -A call for policy change. Indian J Med Pediatr Oncol 43. https:\/\/doi.org\/10.1055\/s-0042-1742651","DOI":"10.1055\/s-0042-1742651"},{"issue":"8","key":"8054_CR39","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/biom12081031","volume":"12","author":"B Costa","year":"2022","unstructured":"Costa B, Vale N, Dostarlimab A, Review (2022) Biomolecules 12(8):1031. https:\/\/doi.org\/10.3390\/biom12081031","journal-title":"Biomolecules"},{"issue":"3","key":"8054_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1245\/s10434-019-08091-3","volume":"27","author":"KU Park","year":"2020","unstructured":"Park KU, Kyrish K, Yi M et al (2020) Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. Ann Surg Oncol 27(3):730\u2013735. https:\/\/doi.org\/10.1245\/s10434-019-08091-3","journal-title":"Ann Surg Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08054-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:49:14Z","timestamp":1787640554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08054-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8054"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08054-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the Declaration of Helsinki. The Human Investigation Committee (IRB) of Massachusetts General Hospital approved this study.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"40"}}